In addition, clinical trial results for the three-drug combination of Dabrafenib + Trametinib + Pembrolizumab showed that the three-drug combination group improved PR and CR in MM patients with resectable stage III BRAF-mutant [112]. The gene discussed is BRAF; the disease is Miyoshi myopathy.